Open AccessA dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR downstream signaling pathways in colorectal cancer
Author(s) -
Linghui Kong,
Qun Zhang,
Jialei Mao,
Lei Cheng,
Xiao Shi,
Lixia Yu,
Jing Hu,
Mi Yang,
Li Li,
Baorui Liu,
Xiaoping Qian
Publication year - 2021
Publication title -
journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
eISSN - 2219-679X
pISSN - 2078-6891
DOI - 10.21037/jgo-21-467
Subject(s) - cancer research , pi3k/akt/mtor pathway , protein kinase b , mapk/erk pathway , cetuximab , medicine , cell growth , kinase , signal transduction , microbiology and biotechnology , cancer , biology , colorectal cancer , biochemistry
Epidermal growth factor receptor (EGFR) and its downstream Ras-mitogen-activated protein kinase kinase (MAPKK, MEK)-extracellular regulated protein kinase (ERK) signaling pathway and phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt)-mammalian target of rapamycin (mTOR) signaling pathway play important roles in the pathogenesis of colorectal cancer (CRC). The combination therapy of anti-EGFR and anti-mTOR needs to be explored.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom